Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 397413
Title C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in the CARDS Study
Author(s) Charlton-Menys, V.; Colhoun, H.M.; Betteridge, D.J.; Soedamah-Muthu, S.S.; Hitman, G.; Neil, A.; Livingstone, S.; Bao, W.; DeMicco, D.A.; Preston, G.M.; Fuller, J.; Durrington, P.
Source Circulation 120 (2009)S398. - ISSN 0009-7322 - p. 823 - 823.
Department(s) Chair Nutrition and Disease
VLAG
Publication type Abstract in scientific journal or proceedings
Publication year 2009
Abstract Background: Inflammatory markers such as C-reactive protein (CRP) and serum amyloid A (sAA) have been proposed as biomarkers of cardiovascular disease (CVD), but information in diabetes is limited. Methods: We measured CRP and sAA (both mg/L) at baseline and after 12 months of treatment in the randomised Collaborative Atorvastatin Diabetes Study (CARDS), which demonstrated efficacy of 10 mg atorvastatin in the primary prevention of CVD in patients with type 2 diabetes. We used results for CRP and sAA available in 87% of the CARDS patients (placebo [n=1215] and atorvastatin [n=1250]) in whom a total of 181 primary events occurred. The median duration of follow-up was 3.9 years. CRP and sAA were measured in plasma using latex particle-enhanced immunonephelometric assays with the BN Prospec® system (Dade-Behring UK Ltd). Time to first CVD event was evaluated by Cox proportional hazards models using quartiles of baseline biomarker concentrations with adjustment for treatment allocation and relevant covariates. Results: At baseline, patients on placebo and atorvastatin had similar concentrations of CRP (median [interquartile range] of 1.5 [0.6 –3.6] vs. 1.3 [0.6 –3.1]) and sAA (3.0 [1.7–5.2] vs. 2.9 [1.6 – 4.9]). CRP correlated with sAA both at baseline and at 12 months (r=0.66 and r=0.65; p0.2). Patients with CVD events had a slight increase in CRP (0.1, [–0.8 –1.3]), not significantly different (p=0.13) from patients without events (0, [–0.9 –1.1]). Similar results were observed for sAA. Conclusion: CRP is reduced by atorvastatin relative to placebo. In these diabetic patients with relatively low baseline CRP, reduction in CVD events from atorvastatin treatment was seen in patients with and without elevated CRP levels.
Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.